---
title: "Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294081196.md"
description: "Wedbush analyst David Nierengarten maintained a Buy rating on Kura Oncology (KURA) with a $36 price target. Concurrently, Barclays also upheld a Buy rating for the stock, setting its price target at $28."
datetime: "2026-07-28T14:17:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294081196.md)
  - [en](https://longbridge.com/en/news/294081196.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294081196.md)
generator: "portal-rs"
---

# Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Kura Oncology, with a price target of $36.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Apogee Therapeutics, and Abivax SA Sponsored ADR. According to TipRanks, Nierengarten has an average return of 22.1% and a 53.57% success rate on recommended stocks. 

In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [Kura Oncology CFO Jennifer Fulk files initial beneficial ownership statement](https://longbridge.com/en/news/298640802.md)
- [Kura Oncology names Jennifer Fulk chief financial officer](https://longbridge.com/en/news/298307125.md)
- [Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financing](https://longbridge.com/en/news/298445580.md)
- [Is Kura Oncology's (KURA) Zacks Upgrade Quietly Reframing Its Precision Oncology Risk‑Reward Story?](https://longbridge.com/en/news/297754554.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**